EGFR, NSCLC
Conditions
Keywords
EGFR, NSCLC, Carboplatin, vinorelbine, Gefitinib
Brief summary
The purpose of this study was to evaluate the efficacy and safety of targeted gefitinib versus oral vinorelbine and carboplatin in EGFR-mutant NSCLC patients.
Detailed description
The purpose of this study was to evaluate the efficacy and safety of targeted gefitinib versus oral vinorelbine and carboplatin in EGFR-mutant NSCLC patients. The purpose is to explore the role of TKI in neoadjuvant therapy, and to further improve disease-free survival (DFS) and pathologic complete remission (pCR) in EGFR-mutant populations; and reduce surgical complications and mortality. OBJECTIVES: To evaluate the efficacy of oral gefitinib versus neoadjuvant vinorelbine and carboplatin in operable stage II-IIIA EGFR-mutant non-squamous NSCLC patients, with a 2-year disease-free survival rate. 2yDFS). Secondary objective: To evaluate pCR, 0RR, and other efficacy measures (safety, complete) for oral gefitinib vs. neoadjuvant vinorelbine and carboplatin in patients with operable stage II-IIIA EGFR-mutant non-squamous cell carcinoma NSCLC. Resection rate, tumor regression, mediastinal lymph node clearance, perioperative complications, and mortality rate).
Interventions
DRUGGefitinib
Gefitinib (250 mg, orally, every day) for 56 days
DRUGVinorelbine
Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
DRUGCarboplatin
Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
Sponsors
Shenzhen People's Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. The pathological diagnosis is non-squamous cell carcinoma and non-small cell lung cancer. The pre-treatment tumor stage is stage II-IIIA; 2. The gene detects EGFR mutations is positive; 3. The age is between 18-70 years; 4. ECOG 0-1; 5. Liver and kidney function and Bone marrow hematopoiesis is normal; 6. There are no serious systemic, respiratory, cardiovascular and other important systemic dysfunctions and severe malnutrition; 7. No other malignant diseases within 5 years; 8. Patients who have not received radiotherapy, systemic chemotherapy, or biological therapy; 9. Understand the whole process of the trial and voluntarily participate in and sign the informed consent form.
Exclusion criteria
1. The tumor has invaded the surrounding tissue; 2. Preoperative evidence suggests that distant metastases of the lesion include contralateral mediastinal lymph node metastasis; 3. Arrhythmias require anti-arrhythmia therapy (β-blocker or digoxin Except), symptomatic coronary artery disease or myocardium. Ischemic or congestive heart failure exceeds NYHA class II; 4. severe hypertension with poor drug control; 5. moderate to severe proteinuria; 6. HIV fluHistory of infection or active chronic hepatitis B or C; 7. Malnutrition, decompensation of organ function; 8. History of chest radiotherapy; 9. Incomplete inflammation of eyes; 10. Patients with seizures that need to be treated; 11. Interstitial pneumonia; 12. Drug abuse and others that may interfere with patients' participation in the study or studyThe assessment of the results has an impact; 13. Allergies to the study drug are known or suspected to be allergic to or administered to any drug associated with this test; 14. Any instability. The condition of the patient may jeopardize patient safety and compliance; 15. Pregnancy or breastfeeding women and having fertility without adequate contraception.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2y DFS | 2 years | 2-year disease-free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 6 months | objective response rates |
Countries
China
Contacts
Primary ContactWang Lingwei, Doctor
Backup ContactWang Guangsuo, Doctor
Outcome results
None listed